Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Kory et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377
Apr 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19ivm.org
Review of ivermectin trials and epidemiological data, concluding that ivermectin is effective for prophylaxis and treatment, and should be globally and systematically deployed in the prevention and treatment of COVID-19.
An update notes potentially inaccurate data collection and/or reporting in some sources journals.lww.com.
Kory et al., 30 Apr 2021, peer-reviewed, 5 authors.
This PaperIvermectinAll
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
MD Pierre Kory, MD Gianfranco Umberto Meduri, MD Joseph Varon, DO Jose Iglesias, MD Paul E Marik, Jose Iglesias Analysis
Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials. Areas of Uncertainty: The majority of trialed agents have failed to provide reproducible, definitive proof of efficacy in reducing the mortality of COVID-19 with the exception of corticosteroids in moderate to severe disease. Recently, evidence has emerged that the oral antiparasitic agent ivermectin exhibits numerous antiviral and anti-inflammatory mechanisms with trial results reporting significant outcome benefits. Given some have not passed peer review, several expert groups including Unitaid/World Health Organization have undertaken a systematic global effort to contact all active trial investigators to rapidly gather the data needed to grade and perform meta-analyses. Data Sources: Data were sourced from published peer-reviewed studies, manuscripts posted to preprint servers, expert meta-analyses, and numerous epidemiological analyses of regions with ivermectin distribution campaigns. Therapeutic Advances: A large majority of randomized and observational controlled trials of ivermectin are reporting repeated, large magnitude improvements in clinical outcomes. Numerous prophylaxis trials demonstrate that regular ivermectin use leads to large reductions in transmission. Multiple, large "natural experiments" occurred in regions that initiated "ivermectin distribution" campaigns followed by tight, reproducible, temporally associated decreases in case counts and case fatality rates compared with nearby regions without such campaigns. Conclusions: Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly
References
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Aguirre-Chang, Post-Acute or prolonged COVID-19: treatment with ivermectin for patietns with persistent, or post-acute symptoms ResearchGate
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Alam, Pfg, Ivermectin as pre-exposure prophylaxis for COVID 19 among healthcare providers in a selected tertiary hospital in Dhaka an observational study, Eur J Med Health Sci
Anglemyer, Horvath, Bero, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, Cochrane Database Syst Rev
Arevalo, Pagotto, Porfido, Ivermectin reduces coronavirus infection in vivo: a mouse experimental model, bioRxiv, doi:10.1101/2020.11
Atkinson, Audsley, Lieu, Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V, Sci Rep
Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate Covid19 disease: a randomised controlled double blind dose response study in Lagos, medRxiv, doi:10.1093/qjmed/hcab035
Behera, Patro, Singh, Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: a matched case-control study
Bernigaud, Guillemot, Ahmed-Belkacem, B en efice de l'ivermectine: de la gale à la COVID-19, un exemple de s erendipit e, Annales de Dermatologie et de V en er eologie
Bray, Rayner, Noël, Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Budhiraja, Soni, Jha, Clinical Profile of First 1000 COVID-19 cases admitted at tertiary care hospitals and the correlates of their mortality: an Indian experience, medRxiv, doi:10.1101/2020.11.16.20232223
Cadegiani, Goren, Wambier, Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients, medRxiv, doi:10.1101/2020.10.31.20223883
Callard, Perego, How and why patients made Long Covid, Soc Sci Med
Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res
Carvallo, Hirsch, Farinella, Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19, doi:10.1101/2020.09.10.20191619v1
Chaccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial, EClini-calMedicine
Chachar, Khan, Asif, Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci
Chala, Covid-19 in healthcare agents by intensive treatment with ivermectin and iotacarrageenan (Ivercar-Tuc)
Chamie, Real-world evidence: the case of Peru
Chandler, Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?, Am J Trop Med Hyg
Chowdhury, Shahbaz, Karim, A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, Res Square, doi:10.21203/rs.3.rs-38896/v1
Ci, Li, Yu, Avermectin exerts antiinflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol
Consortium, Repurposed antiviral drugs for covid-19-interim WHO solidarity trial results, New Engl J Med
Crump, Omura, Ivermectin,'wonder drug'from Japan: the human use perspective, Proc Jpn Acad Ser B
Dahabreh, Sheldrick, Paulus, Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes, Eur Heart J
Dasgupta, Sen, Bakshi, Nsp7 and spike glycoprotein of SARS-CoV-2 are envisaged as potential targets of vitamin D and ivermectin, doi:10.20944/preprints202005.0084.v1
Dayer, Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding by old drugs, bioinformatic study, doi:10.20944/preprints202005.0020.v1
De Melo, Lazarini, Larrous, Anti-COVID-19 efficacy of ivermectin in the golden hamster, bioRxiv, doi:10.1101/2020.11.21.392639
Elgazzar, Hany, Youssef, Hafez, Moussa, Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic, Res Square, doi:10.21203/rs.3.rs-100956/v3
Espitia-Hernandez, Munguia, Diaz-Chiguer, Effects of Ivermectin-Azithromycin-Cholecalciferol Combined Therapy on COVID-19 Infected Patients: A Proof of Concept Study
Gardon, Gardon-Wendel, Demanga, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection, Lancet
Gorial, Mashhadani, Sayaly, Effectiveness of ivermectin as add-on therapy in COVID-19 management, medRxiv, doi:10.1101/2020.07.07.20145979
Gupta, Biswal, Panda, Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin, J Biomol Struct Dyn
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol
Götz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep
H Ector, Roberto, Psaltis, Study of the efficacy and safety of topical ivermectin+ iota-carrageenan in the prophylaxis against COVID-19 in health personnel, J Biomed Res Clin Investig
Hashim, Maulood, Rasheed, Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq, doi:10.1101/2020.10.26.20219345
Hellwig, A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin, Int J Antimicrob Agents
Hermine, Tharaux, Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial, JAMA Intern Med
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with Covid-19-preliminary report, New Engl J Med
Hussien, Abdelaziz, Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease, Netw Model Anal Health Inform Bioinform
Khan, Khan, Debnath, Ivermectin treatment may improve the prognosis of patients with COVID-19, Archivos de Bronconeumología
King, Tessier, Dodge, Inhibition of human adenovirus replication by the importin a/b1 nuclear import inhibitor ivermectin, J Virol
Kircik, Rosso, Layton, Over 25 Years of clinical experience with ivermectin: an overview of safety for an increasing number of indications, J Drugs Dermatol
Kitsios, Dahabreh, Callahan, Can we trust observational studies using propensity scores in the critical care literature? A systematic comparison with randomized clinical trials, Crit Care Med
Kylie, Sivakumaran, Steven, Ivermectin is a specific inhibitor of importin a/b-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, Vivo
Li, Chen, Cao, Extraordinary GU-rich singlestrand RNA identified from SARS coronavirus contributes an excessive immune response, Microbes Infect
Lonjon, Boutron, Trinquart, Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures, Ann Surg
Lv, Liu, Wang, Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antivir Res
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother
Maurya, A combination of ivermectin and doxycycline possibly blocks the viral entry and modulate the innate immune response in COVID-19 patients, ChemRxiv, doi:10.26434/chemrxiv.12630539.v1
Morgenstern, Redondo, Leon, The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may, doi:10.1101/2020.10.29.20222505
Nallusamy, Mannu, Ravikumar, Shortlisting phytochemicals exhibiting inhibitory activity against major proteins of SARS-CoV-2 through virtual screening, Res Square, doi:10.21203/rs.3.rs-31834/v1
Niaee, Gheibi, Namdar, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial, Res Square, doi:10.21203/rs.3.rs-109670/v1
Perera, Tso, Tsang, SARS-CoV-2 virus culture from the upper respiratory tract: correlation with viral load, subgenomic viral RNA and duration of illness, MedRXiv, doi:10.1101/2020.07.08.20148783
Podder, Chowdhury, Sina, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC J Med Sci
Polak, Van Gool, Cohen, A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression, Mod Pathol
Portmann-Baracco, Alberti, Accinelli, Antiviral and anti-inflammatory properties of ivermectin and its potential use in covid-19, Arch Bronconeumol
Rajter, Sherman, Fatteh, Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19 (ICON study), Chest
Randomized, Double-Blind Placebo Controlled Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection Clinical-Trials
Ravikirti, Pattadar, Ivermectin as a potential treatment for mild to moderate COVID-19 -a double blind randomized placebo-controlled trial, medRxiv, doi:10.1101/2021.01.05.21249310
Robin, Alam, Saber, A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline, J Bangladesh Coll Physicians Surgeons, doi:10.3329/jbcps.v38i0.47512
Rubin, As their numbers grow, COVID-19 "long haulers" stump experts, JAMA
Salvarani, Dolci, Massari, Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial, JAMA Intern Med
Scheim, From cold to killer: how SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, then clot blood cells in pulmonary and systemic microvasculature, doi:10.2139/ssrn.3706347
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther
Shouman, Hegazy, Nafae, Use of Ivermectin as a Potential Chemoprophylaxis for COV-ID-19 in Egypt: A Randomized Clinical Trial, J Clin Diagn Res
Siegelman, Reflections of a COVID-19 long hauler, JAMA
Soto-Becerra, Culquichicón, Hurtado-Roca, Realworld effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
Sparsa, Bonnetblanc, Peyrot, Systemic adverse reactions with ivermectin treatment of scabies, Annales de Dermatologie et de Venereologie
Spoorthi, Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV2, Int Arch Integrated Med
Suravajhala, Parashar, Malik, Comparative docking studies on curcumin with COVID-19 proteins, doi:10.20944/preprints202005.0439.v1
Swargiary, Ivermectin as a Promising RNA-dependent RNA Polymerase Inhibitor and a Therapeutic Drug against SARS-CoV2: Evidence from in Silico Studies, Res Square, doi:10.21203/rs.3.rs-73308/v1
Tambo, Khater, Chen, Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty, Infect Dis Poverty
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Res
Varghese, Kaukinen, Gläsker, Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir Res
Veit, Beck, Steuerwald, First case of ivermectin-induced severe hepatitis, Trans R Soc Trop Med Hyg
Yang, Atkinson, Wang, The broad spectrum antiviral ivermectin targets the host nuclear transport importin a/b1 heterodimer, Antivir Res
Young, Ong, Ng, Viral dynamics and immune correlates of COVID-19 disease severity, Clin Infect Dis
Zhang, Song, Ci, Ivermectin inhibits LPSinduced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res
Zhang, Song, Xiong, Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol
{ 'DOI': '10.1097/mjt.0000000000001377', 'ISSN': ['1075-2765'], 'URL': 'http://dx.doi.org/10.1097/MJT.0000000000001377', 'abstract': '<jats:sec>\n' ' <jats:title>Background:</jats:title>\n' ' <jats:p>After COVID-19 emerged on U.S shores, providers began reviewing the ' 'emerging basic science, translational, and clinical data to identify potentially effective ' 'treatment options. In addition, a multitude of both novel and repurposed therapeutic agents ' 'were used empirically and studied within clinical trials.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Areas of Uncertainty:</jats:title>\n' ' <jats:p>The majority of trialed agents have failed to provide reproducible, ' 'definitive proof of efficacy in reducing the mortality of COVID-19 with the exception of ' 'corticosteroids in moderate to severe disease. Recently, evidence has emerged that the oral ' 'antiparasitic agent ivermectin exhibits numerous antiviral and anti-inflammatory mechanisms ' 'with trial results reporting significant outcome benefits. Given some have not passed peer ' 'review, several expert groups including Unitaid/World Health Organization have undertaken a ' 'systematic global effort to contact all active trial investigators to rapidly gather the data ' 'needed to grade and perform meta-analyses.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Data Sources:</jats:title>\n' ' <jats:p>Data were sourced from published peer-reviewed studies, manuscripts ' 'posted to preprint servers, expert meta-analyses, and numerous epidemiological analyses of ' 'regions with ivermectin distribution campaigns.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Therapeutic Advances:</jats:title>\n' ' <jats:p>A large majority of randomized and observational controlled trials of ' 'ivermectin are reporting repeated, large magnitude improvements in clinical outcomes. ' 'Numerous prophylaxis trials demonstrate that regular ivermectin use leads to large reductions ' 'in transmission. Multiple, large “natural experiments” occurred in regions that initiated ' '“ivermectin distribution” campaigns followed by tight, reproducible, temporally associated ' 'decreases in case counts and case fatality rates compared with nearby regions without such ' 'campaigns.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions:</jats:title>\n' ' <jats:p>Meta-analyses based on 18 randomized controlled treatment trials of ' 'ivermectin in COVID-19 have found large, statistically significant reductions in mortality, ' 'time to clinical recovery, and time to viral clearance. Furthermore, results from numerous ' 'controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with ' 'the regular use of ivermectin. Finally, the many examples of ivermectin distribution ' 'campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that ' 'an oral agent effective in all phases of COVID-19 has been identified.</jats:p>\n' ' </jats:sec>', 'author': [ { 'affiliation': [{'name': 'Front-Line Covid-19 Critical Care Alliance, Madison, WI;'}], 'family': 'Kory', 'given': 'Pierre', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Memphis VA Medical Center—University of Tennessee Health Science ' 'Center, Pulmonary, Critical Care, and Research Services, ' 'Memphis, TN;'}], 'family': 'Meduri', 'given': 'Gianfranco Umberto', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'University of Texas Health Science Center, Critical Care ' 'Service, Houston, TX;'}], 'family': 'Varon', 'given': 'Joseph', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Medicine, Hackensack School of Medicine, Seton ' 'Hall, NJ; and'}], 'family': 'Iglesias', 'given': 'Jose', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Eastern Virginia Medical School, Division of Pulmonary and ' 'Critical Care, Norfolk, VA.'}], 'family': 'Marik', 'given': 'Paul E.', 'sequence': 'additional'}], 'container-title': 'American Journal of Therapeutics', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 5, 5]], 'date-time': '2021-05-05T12:33:02Z', 'timestamp': 1620217982000}, 'deposited': { 'date-parts': [[2023, 9, 17]], 'date-time': '2023-09-17T04:17:18Z', 'timestamp': 1694924238000}, 'indexed': {'date-parts': [[2024, 5, 3]], 'date-time': '2024-05-03T18:40:09Z', 'timestamp': 1714761609574}, 'is-referenced-by-count': 100, 'issue': '3', 'issued': {'date-parts': [[2021, 4, 22]]}, 'journal-issue': {'issue': '3', 'published-online': {'date-parts': [[2021]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/', 'content-version': 'unspecified', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 4, 22]], 'date-time': '2021-04-22T00:00:00Z', 'timestamp': 1619049600000}}], 'link': [ { 'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001377', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '276', 'original-title': [], 'page': 'e299-e318', 'prefix': '10.1097', 'published': {'date-parts': [[2021, 4, 22]]}, 'published-online': {'date-parts': [[2021, 5]]}, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'reference': [ { 'DOI': '10.1001/jamainternmed.2020.6820', 'article-title': 'Effect of tocilizumab vs usual care in adults hospitalized with ' 'COVID-19 and moderate or severe pneumonia: a randomized clinical trial', 'author': 'Hermine', 'doi-asserted-by': 'crossref', 'first-page': '32', 'journal-title': 'JAMA Intern Med.', 'key': 'R1-20230917', 'volume': '181', 'year': '2021'}, { 'DOI': '10.1001/jamainternmed.2020.6615', 'article-title': 'Effect of tocilizumab vs standard care on clinical worsening in ' 'patients hospitalized with COVID-19 pneumonia: a randomized clinical ' 'trial', 'author': 'Salvarani', 'doi-asserted-by': 'crossref', 'first-page': '24', 'journal-title': 'JAMA Intern Med.', 'key': 'R2-20230917', 'volume': '181', 'year': '2021'}, { 'DOI': '10.1136/bmj.m3939', 'article-title': 'Convalescent plasma in the management of moderate covid-19 in adults in ' 'India: open label phase II multicentre randomised controlled trial ' '(PLACID Trial)', 'author': 'Agarwal', 'doi-asserted-by': 'crossref', 'first-page': 'm3939', 'journal-title': 'BMJ', 'key': 'R3-20230917', 'volume': '371', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2023184', 'article-title': 'Repurposed antiviral drugs for covid-19— interim WHO solidarity trial ' 'results', 'author': 'Consortium', 'doi-asserted-by': 'crossref', 'first-page': '497', 'journal-title': 'New Engl J Med.', 'key': 'R4-20230917', 'volume': '384', 'year': '2020'}, { 'article-title': 'Dexamethasone in hospitalized patients with Covid-19-preliminary report', 'author': 'Horby', 'first-page': '693', 'journal-title': 'New Engl J Med.', 'key': 'R6-20230917', 'volume': '384', 'year': '2020'}, { 'DOI': '10.2183/pjab.87.13', 'article-title': 'Ivermectin,‘wonder drug’from Japan: the human use perspective', 'author': 'Crump', 'doi-asserted-by': 'crossref', 'first-page': '13', 'journal-title': 'Proc Jpn Acad Ser B', 'key': 'R7-20230917', 'volume': '87', 'year': '2011'}, { 'DOI': '10.1186/s40249-015-0091-8', 'article-title': 'Nobel prize for the artemisinin and ivermectin discoveries: a great ' 'boost towards elimination of the global infectious diseases of poverty', 'author': 'Tambo', 'doi-asserted-by': 'crossref', 'first-page': '58', 'journal-title': 'Infect Dis Poverty', 'key': 'R8-20230917', 'volume': '4', 'year': '2015'}, { 'DOI': '10.1038/s41598-017-18742-8', 'article-title': 'Recognition by host nuclear transport proteins drives disorder-to-order ' 'transition in Hendra virus V', 'author': 'Atkinson', 'doi-asserted-by': 'crossref', 'first-page': '358', 'journal-title': 'Sci Rep.', 'key': 'R9-20230917', 'volume': '8', 'year': '2018'}, { 'DOI': '10.1016/j.antiviral.2020.104760', 'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer', 'author': 'Yang', 'doi-asserted-by': 'crossref', 'first-page': '104760', 'journal-title': 'Antivir Res', 'key': 'R10-20230917', 'volume': '177', 'year': '2020'}, { 'DOI': '10.1038/srep23138', 'article-title': 'Influenza A viruses escape from MxA restriction at the expense of ' 'efficient nuclear vRNP import', 'author': 'Götz', 'doi-asserted-by': 'crossref', 'first-page': '23138', 'journal-title': 'Sci Rep.', 'key': 'R11-20230917', 'volume': '6', 'year': '2016'}, { 'DOI': '10.1016/j.antiviral.2018.09.010', 'article-title': 'Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance ' 'into the nucleus and proliferation of the virus in vitro and vivo', 'author': 'Lv', 'doi-asserted-by': 'crossref', 'first-page': '55', 'journal-title': 'Antivir Res', 'key': 'R12-20230917', 'volume': '159', 'year': '2018'}, { 'DOI': '10.1093/jac/dks147', 'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically ' 'targeting NS3 helicase activity: new prospects for an old drug', 'author': 'Mastrangelo', 'doi-asserted-by': 'crossref', 'first-page': '1884', 'journal-title': 'J Antimicrob Chemother.', 'key': 'R13-20230917', 'volume': '67', 'year': '2012'}, { 'DOI': '10.1016/j.antiviral.2013.06.002', 'article-title': 'Nuclear localization of dengue virus (DENV) 1–4 non-structural protein ' '5; protection against all 4 DENV serotypes by the inhibitor Ivermectin', 'author': 'Tay', 'doi-asserted-by': 'crossref', 'first-page': '301', 'journal-title': 'Antiviral Res.', 'key': 'R14-20230917', 'volume': '99', 'year': '2013'}, { 'DOI': '10.1016/j.antiviral.2015.12.012', 'article-title': 'Discovery of berberine, abamectin and ivermectin as antivirals against ' 'chikungunya and other alphaviruses', 'author': 'Varghese', 'doi-asserted-by': 'crossref', 'first-page': '117', 'journal-title': 'Antivir Res', 'key': 'R15-20230917', 'volume': '126', 'year': '2016'}, { 'DOI': '10.1042/BJ20120150', 'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear ' 'import able to inhibit replication of HIV-1 and dengue virus', 'author': 'Wagstaff Kylie', 'doi-asserted-by': 'crossref', 'first-page': '851', 'journal-title': 'Biochem J.', 'key': 'R16-20230917', 'volume': '443', 'year': '2012'}, { 'DOI': '10.1128/JVI.00710-20', 'article-title': 'Inhibition of human adenovirus replication by the importin α/β1 nuclear ' 'import inhibitor ivermectin', 'author': 'King', 'doi-asserted-by': 'crossref', 'first-page': '94', 'journal-title': 'J Virol.', 'key': 'R17-20230917', 'volume': '94', 'year': '2020'}, { 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'author': 'Caly', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'journal-title': 'Antivir Res', 'key': 'R18-20230917', 'volume': '178', 'year': '2020'}, { 'DOI': '10.1016/j.antiviral.2020.104805', 'article-title': 'Ivermectin and COVID-19: a report in Antiviral Research, widespread ' "interest, an FDA warning, two letters to the editor and the authors' " 'responses', 'author': 'Bray', 'doi-asserted-by': 'crossref', 'first-page': '104805', 'journal-title': 'Antiviral Res.', 'key': 'R19-20230917', 'volume': '178', 'year': '2020'}, { 'article-title': 'The approved dose of ivermectin alone is not the ideal dose for the ' 'treatment of COVID‐19', 'author': 'Schmith', 'first-page': '214', 'journal-title': 'Clin Pharmacol Ther.', 'key': 'R20-20230917', 'volume': '103', 'year': '2020'}, { 'article-title': 'Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding ' 'by old drugs, bioinformatic study', 'author': 'Dayer', 'journal-title': 'Preprints', 'key': 'R21-20230917', 'year': '2020'}, { 'article-title': 'A combination of ivermectin and doxycycline possibly blocks the viral ' 'entry and modulate the innate immune response in COVID-19 patients', 'author': 'Maurya', 'journal-title': 'ChemRxiv', 'key': 'R22-20230917', 'year': '2020'}, { 'DOI': '10.1007/s13721-020-00263-6', 'article-title': 'Molecular docking suggests repurposing of brincidofovir as a potential ' 'drug targeting SARS-CoV-2 ACE2 receptor and main protease', 'author': 'Hussien', 'doi-asserted-by': 'crossref', 'first-page': '56', 'journal-title': 'Netw Model Anal Health Inform Bioinform', 'key': 'R23-20230917', 'volume': '9', 'year': '2020'}, { 'DOI': '10.21873/invivo.12134', 'article-title': 'Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain ' 'attached to ACE2', 'author': 'Lehrer', 'doi-asserted-by': 'crossref', 'first-page': '3023', 'journal-title': 'Vivo', 'key': 'R26-20230917', 'volume': '34', 'year': '2020'}, { 'article-title': 'Nsp7 and spike glycoprotein of SARS-CoV-2 are envisaged as potential ' 'targets of vitamin D and ivermectin', 'author': 'Dasgupta', 'journal-title': 'Preprints', 'key': 'R28-20230917', 'year': '2020'}, { 'article-title': 'Binding mechanism and structural insights into the identified protein ' 'target of COVID-19 and importin-alpha with in-vitro effective drug ' 'ivermectin', 'author': 'Sen Gupta', 'first-page': '1', 'journal-title': 'J Biomol Struct Dyn.', 'key': 'R29-20230917', 'year': '2020'}, { 'article-title': 'Ivermectin reduces coronavirus infection in vivo: a mouse experimental ' 'model', 'author': 'Arevalo', 'journal-title': 'bioRxiv', 'key': 'R31-20230917', 'year': '2020'}, { 'article-title': 'Anti-COVID-19 efficacy of ivermectin in the golden hamster', 'author': 'de Melo', 'journal-title': 'bioRxiv', 'key': 'R32-20230917', 'year': '2020'}, { 'article-title': 'SARS-CoV-2 virus culture from the upper respiratory tract: correlation ' 'with viral load, subgenomic viral RNA and duration of illness', 'author': 'Perera', 'journal-title': 'MedRXiv', 'key': 'R33-20230917', 'year': '2020'}, { 'DOI': '10.1038/s41379-020-0603-3', 'article-title': 'A systematic review of pathological findings in COVID-19: a ' 'pathophysiological timeline and possible mechanisms of disease ' 'progression', 'author': 'Polak', 'doi-asserted-by': 'crossref', 'first-page': '2128', 'journal-title': 'Mod Pathol.', 'key': 'R34-20230917', 'volume': '33', 'year': '2020'}, { 'article-title': 'Viral dynamics and immune correlates of COVID-19 disease severity', 'author': 'Young', 'journal-title': 'Clin Infect Dis.', 'key': 'R35-20230917', 'year': '2020'}, { 'DOI': '10.1016/j.micinf.2012.10.008', 'article-title': 'Extraordinary GU-rich single-strand RNA identified from SARS ' 'coronavirus contributes an excessive innate immune response', 'author': 'Li', 'doi-asserted-by': 'crossref', 'first-page': '88', 'journal-title': 'Microbes Infect.', 'key': 'R36-20230917', 'volume': '15', 'year': '2013'}, { 'DOI': '10.1016/j.intimp.2008.12.016', 'article-title': 'Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 ' 'production in LPS-stimulated RAW 264.7 macrophages', 'author': 'Zhang', 'doi-asserted-by': 'crossref', 'first-page': '354', 'journal-title': 'Int Immunopharmacol', 'key': 'R37-20230917', 'volume': '9', 'year': '2009'}, { 'DOI': '10.1111/j.1472-8206.2009.00684.x', 'article-title': 'Avermectin exerts anti-inflammatory effect by downregulating the ' 'nuclear transcription factor kappa-B and mitogen-activated protein ' 'kinase activation pathway', 'author': 'Ci', 'doi-asserted-by': 'crossref', 'first-page': '449', 'journal-title': 'Fundam Clin Pharmacol.', 'key': 'R38-20230917', 'volume': '23', 'year': '2009'}, { 'DOI': '10.1007/s00011-008-8007-8', 'article-title': 'Ivermectin inhibits LPS-induced production of inflammatory cytokines ' 'and improves LPS-induced survival in mice', 'author': 'Zhang', 'doi-asserted-by': 'crossref', 'first-page': '524', 'journal-title': 'Inflamm Res.', 'key': 'R39-20230917', 'volume': '57', 'year': '2008'}, { 'article-title': 'Role of ivermectin in the prevention of COVID-19 infection among ' 'healthcare workers in India: a matched case-control study', 'author': 'Behera', 'journal-title': 'medRxiv', 'key': 'R41-20230917', 'year': '2020'}, { 'DOI': '10.1016/j.ijantimicag.2020.106248', 'article-title': 'A COVID-19 Prophylaxis? Lower incidence associated with prophylactic ' 'administration of Ivermectin', 'author': 'Hellwig', 'doi-asserted-by': 'crossref', 'first-page': '106248', 'journal-title': 'Int J Antimicrob Agents', 'key': 'R42-20230917', 'volume': '57', 'year': '2021'}, { 'article-title': 'Covid-19 in healthcare agents by intensive treatment with ivermectin ' 'and iota-carrageenan (Ivercar-Tuc)', 'author': 'Prophylaxis', 'first-page': 'NCT04701710', 'journal-title': 'ClinicalTrials.gov', 'key': 'R46-20230917', 'year': '2020'}, { 'article-title': 'Ivermectin as pre-exposure prophylaxis for COVID 19 among healthcare ' 'providers in a selected tertiary hospital in Dhaka an observational ' 'study', 'author': 'Alam', 'first-page': '1', 'journal-title': 'Eur J Med Health Sci.', 'key': 'R47-20230917', 'volume': '2', 'year': '2020'}, { 'article-title': 'Safety and Efficacy of the combined use of ivermectin, dexamethasone, ' 'enoxaparin and aspirin against COVID-19', 'author': 'Carvallo', 'journal-title': 'medRxiv', 'key': 'R50-20230917', 'year': '2020'}, { 'DOI': '10.1016/j.arbres.2020.08.007', 'article-title': 'Ivermectin treatment may improve the prognosis of patients with ' 'COVID-19', 'author': 'Khan', 'doi-asserted-by': 'crossref', 'first-page': '828', 'journal-title': 'Archivos de Bronconeumología', 'key': 'R51-20230917', 'volume': '56', 'year': '2020'}, { 'article-title': 'Effectiveness of ivermectin as add-on therapy in COVID-19 management ' '(pilot trial)', 'author': 'Gorial', 'journal-title': 'medRxiv', 'key': 'R52-20230917', 'year': '2020'}, { 'article-title': 'Controlled randomized clinical trial on using Ivermectin with ' 'Doxycycline for treating COVID-19 patients in Baghdad, Iraq', 'author': 'Hashim', 'journal-title': 'medRxiv', 'key': 'R53-20230917', 'year': '2020'}, { 'article-title': 'Outcome of ivermectin treated mild to moderate COVID-19 cases: a ' 'single-centre, open-label, randomised controlled study', 'author': 'Podder', 'first-page': '1', 'journal-title': 'IMC J Med Sci.', 'key': 'R55-20230917', 'volume': '14', 'year': '2020'}, { 'article-title': 'Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin ' 'or hydroxychloroquine in outpatient settings significantly reduced ' 'symptoms compared to known outcomes in untreated patients', 'author': 'Cadegiani', 'journal-title': 'medRxiv', 'key': 'R56-20230917', 'year': '2020'}, { 'article-title': 'Ivermectin shows clinical benefits in mild to moderate Covid19 disease: ' 'a randomised controlled double blind dose response study in Lagos', 'author': 'Babalola', 'journal-title': 'medRxiv', 'key': 'R59-20230917', 'year': '2021'}, { 'article-title': 'Ivermectin as a potential treatment for mild to moderate COVID-19 – a ' 'double blind randomized placebo-controlled trial', 'author': 'Ravikirti', 'journal-title': 'medRxiv', 'key': 'R60-20230917', 'year': '2021'}, { 'article-title': 'The use of compassionate Ivermectin in the management of symptomatic ' 'outpatients and hospitalized patients with clinical diagnosis of ' 'COVID-19 at the Medical Center Bournigal and the Medical Center Punta ' 'Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020', 'author': 'Morgenstern', 'journal-title': 'medRxiv', 'key': 'R61-20230917', 'year': '2020'}, { 'article-title': 'A case series of 100 COVID-19 positive patients treated with ' 'combination of ivermectin and doxycycline', 'author': 'Robin', 'first-page': '10', 'journal-title': 'J Bangladesh Coll Physicians Surgeons', 'key': 'R62-20230917', 'volume': '38', 'year': '2020'}, { 'DOI': '10.1016/j.chest.2020.10.009', 'article-title': 'Use of ivermectin is associated with lower mortality in hospitalized ' 'patients with COVID-19 (ICON study)', 'author': 'Rajter', 'doi-asserted-by': 'crossref', 'first-page': '85', 'journal-title': 'Chest', 'key': 'R63-20230917', 'volume': '159', 'year': '2021'}, { 'article-title': 'Utility of ivermectin and doxycycline combination for the treatment of ' 'SARS-CoV2', 'author': 'Spoorthi', 'first-page': '177', 'journal-title': 'Int Arch Integrated Med.', 'key': 'R64-20230917', 'volume': '7', 'year': '2020'}, { 'DOI': '10.1016/j.arbres.2020.06.011', 'article-title': 'Antiviral and anti-inflammatory properties of ivermectin and its ' 'potential use in covid-19', 'author': 'Portmann-Baracco', 'doi-asserted-by': 'crossref', 'first-page': '831', 'journal-title': 'Arch Bronconeumol', 'key': 'R66-20230917', 'volume': '56', 'year': '2020'}, { 'DOI': '10.1016/j.ijid.2020.11.191', 'article-title': 'A five day course of ivermectin for the treatment of COVID-19 may ' 'reduce the duration of illness', 'author': 'Ahmed', 'doi-asserted-by': 'crossref', 'first-page': '214', 'journal-title': 'Int J Infect Dis.', 'key': 'R67-20230917', 'volume': '103', 'year': '2021'}, { 'article-title': 'Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients', 'author': 'Chachar', 'first-page': '31', 'journal-title': 'Int J Sci.', 'key': 'R68-20230917', 'volume': '9', 'year': '2020'}, { 'article-title': 'Clinical Profile of First 1000 COVID-19 cases admitted at tertiary care ' 'hospitals and the correlates of their mortality: an Indian experience', 'author': 'Budhiraja', 'journal-title': 'medRxiv.', 'key': 'R70-20230917', 'year': '2020'}, { 'DOI': '10.1001/jama.2020.17709', 'article-title': 'As their numbers grow, COVID-19 “long haulers” stump experts', 'author': 'Rubin', 'doi-asserted-by': 'crossref', 'first-page': '1381', 'journal-title': 'JAMA', 'key': 'R71-20230917', 'volume': '324', 'year': '2020'}, { 'DOI': '10.1016/j.socscimed.2020.113426', 'article-title': 'How and why patients made Long Covid', 'author': 'Callard', 'doi-asserted-by': 'crossref', 'first-page': '113426', 'journal-title': 'Soc Sci Med.', 'key': 'R72-20230917', 'volume': '268', 'year': '2021'}, { 'DOI': '10.1001/jama.2020.22130', 'article-title': 'Reflections of a COVID-19 long hauler', 'author': 'Siegelman', 'doi-asserted-by': 'crossref', 'first-page': '2031', 'journal-title': 'JAMA', 'key': 'R73-20230917', 'volume': '324', 'year': '2020'}, { 'article-title': 'Over 25 Years of clinical experience with ivermectin: an overview of ' 'safety for an increasing number of indications', 'author': 'Kircik', 'first-page': '325', 'journal-title': 'J Drugs Dermatol.', 'key': 'R75-20230917', 'volume': '15', 'year': '2016'}, { 'DOI': '10.1016/S0140-6736(96)11094-1', 'article-title': 'Serious reactions after mass treatment of onchocerciasis with ' 'ivermectin in an area endemic for Loa loa infection', 'author': 'Gardon', 'doi-asserted-by': 'crossref', 'first-page': '18', 'journal-title': 'Lancet', 'key': 'R76-20230917', 'volume': '350', 'year': '1997'}, { 'DOI': '10.1177/009127002237994', 'article-title': 'Safety, tolerability, and pharmacokinetics of escalating high doses of ' 'ivermectin in healthy adult subjects', 'author': 'Guzzo', 'doi-asserted-by': 'crossref', 'first-page': '1122', 'journal-title': 'J Clin Pharmacol.', 'key': 'R77-20230917', 'volume': '42', 'year': '2002'}, { 'DOI': '10.1016/j.trstmh.2006.02.003', 'article-title': 'First case of ivermectin-induced severe hepatitis', 'author': 'Veit', 'doi-asserted-by': 'crossref', 'first-page': '795', 'journal-title': 'Trans R Soc Trop Med Hyg.', 'key': 'R78-20230917', 'volume': '100', 'year': '2006'}, { 'article-title': 'Systemic adverse reactions with ivermectin treatment of scabies', 'author': 'Sparsa', 'first-page': '784', 'key': 'R79-20230917', 'volume': '133', 'year': '2006'}, { 'DOI': '10.4269/ajtmh.17-0042', 'article-title': 'Serious neurological adverse events after ivermectin—do they occur ' 'beyond the indication of onchocerciasis?', 'author': 'Chandler', 'doi-asserted-by': 'crossref', 'first-page': '382', 'journal-title': 'Am J Trop Med Hyg.', 'key': 'R80-20230917', 'volume': '98', 'year': '2018'}, { 'article-title': 'Healthcare outcomes assessed with observational study designs compared ' 'with those assessed in randomized trials', 'author': 'Anglemyer', 'first-page': 'MR000034', 'journal-title': 'Cochrane Database Syst Rev.', 'key': 'R81-20230917', 'year': '2014'}, { 'DOI': '10.1093/eurheartj/ehs114', 'article-title': 'Do observational studies using propensity score methods agree with ' 'randomized trials? A systematic comparison of studies on acute coronary ' 'syndromes', 'author': 'Dahabreh', 'doi-asserted-by': 'crossref', 'first-page': '1893', 'journal-title': 'Eur Heart J.', 'key': 'R82-20230917', 'volume': '33', 'year': '2012'}, { 'DOI': '10.1097/CCM.0000000000001135', 'article-title': 'Can we trust observational studies using propensity scores in the ' 'critical care literature? A systematic comparison with randomized ' 'clinical trials', 'author': 'Kitsios', 'doi-asserted-by': 'crossref', 'first-page': '1870', 'journal-title': 'Crit Care Med.', 'key': 'R83-20230917', 'volume': '43', 'year': '2015'}, { 'DOI': '10.1097/SLA.0000000000000256', 'article-title': 'Comparison of treatment effect estimates from prospective nonrandomized ' 'studies with propensity score analysis and randomized controlled trials ' 'of surgical procedures', 'author': 'Lonjon', 'doi-asserted-by': 'crossref', 'first-page': '18', 'journal-title': 'Ann Surg.', 'key': 'R84-20230917', 'volume': '259', 'year': '2014'}], 'reference-count': 67, 'references-count': 67, 'relation': {}, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001377'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and ' 'Treatment of COVID-19', 'type': 'journal-article', 'volume': '28'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit